Phase I Study of the Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Naxitamab (Primary) ; Cyclophosphamide; Interleukin-2
- Indications Neuroblastoma
- Focus Therapeutic Use
- 01 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 01 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 14 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.